-
公开(公告)号：BG101112A
公开(公告)日：1998-04-30
申请号：BG10111297
申请日：1997-01-06
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBAUH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , IESCHENDORF HANS-JUERGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: The invention relates to the use of heterocyclic compoundswith the formula Het-A-Ar, where Het, A, B & Ar have the meaningslisted in the description. The compounds have high affinity todiopamin-D3-receptors and for this reason are used for thetreatment of diseases reacting to dopamin-D3-ligands.12 claims
-
公开(公告)号：MX9700430A
公开(公告)日：1998-05-31
申请号：MX9700430
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MULLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE CARSTEN
IPC: A61K31/33 , A61K31/415 , A61K31/44 , C07D233/84 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: La presente invencion se refiere al uso de compuestos heterocíclicos de la formula general: Het-A-B-Ar donde Het, A, B y Ar tienen los significados establecidos en la descripcion. Los compuestos de conformidad con la presente invencion tiene una alta afinidad para el receptor D3 de la dopamina y pueden por consiguiente emplearse para tratar trastornos que responden a ligandos de D3 de dopamina.
-
公开(公告)号：SI9520081A
公开(公告)日：1997-08-31
申请号：SI9520081
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE CARSTEN
IPC: C07D277/22 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/54 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/42 , C07D285/12 , C07D285/125 , C07D285/135 , C07D417/12
Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.
-
公开(公告)号：BR9508296A
公开(公告)日：1998-05-19
申请号：BR9508296
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , RENDENDACH-MULLER BEATRICE , LANSKY ANNEGRET , WICKE CARSTEN , TESCHENDORF HANS-JUERGEN , BACH ALFRED , UNGER LILIANE
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：SI9520084A
公开(公告)日：1997-08-31
申请号：SI9520084
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGERET , BACH ALFRED , RENDENBACH-MUELLER BEATRICE , UNGER LILIANE , WICKE CARSTEN , TESCHENDORF HANS-JURGEN
IPC: A61K31/33 , A61K31/415 , A61K31/44 , C07D233/84 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
Patent Agency Ranking
公开(公告)号：CZ9697A3
公开(公告)日：1997-08-13
申请号：CZ9697
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MULLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：DE59510635D1
公开(公告)日：2003-05-15
申请号：DE59510635
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：AT236629T
公开(公告)日：2003-04-15
申请号：AT95926896
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：BG63487B1
公开(公告)日：2002-03-29
申请号：BG10111297
申请日：1997-01-06
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MUELLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JUERGEN , WICKE CARSTEN
IPC: C07D233/84 , A61K31/33 , A61K31/415 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: The invention relates to the use of heterocyclic compounds with the formula Het-A-Ar, where Het, A, B & Ar have the meanings listed in the description. The compounds have high affinity to diopamin-D3-receptors and for this reason are used for the treatment of diseases reacting to dopamin-D3-ligands. 12 claims
-
公开(公告)号：NZ290388A
公开(公告)日：2001-04-27
申请号：NZ29038895
申请日：1995-07-14
Applicant: BASF AG
Inventor： HELLENDAHL BEATE , LANSKY ANNEGRET , RENDENBACH-MULLER BEATRICE , BACH ALFRED , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE CARSTEN
IPC: A61K31/33 , A61K31/415 , A61K31/44 , C07D233/84 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/445 , A61K31/495 , A61K31/496 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/73 , C07D213/79 , C07D213/81 , C07D233/90 , C07D307/79 , C07D333/24 , C07D333/28 , C07D333/38 , C07D471/18
Abstract: Use of a compound of the formula Het-A-B-Ar and the salts thereof with physiologically tolerated acids, in the manufacture of a medicament for treating disorders that respond to dopamine D3 receptor antagonists, wherein: A is a straight or branched alkylene group which contains at least one group which is selected from among O, S, NR4, CONR4, NR4 CO, COO, and OCO; B is a radical of formulae (I); Ar is a phenyl, pyridyl, pyrimidyl or triazinyl, where Ar may have one to four substituents selected from the group consisting of OR4, alkyl, alkenyl, alkynyl, halogen, CN, CO2R4, NO2, SO2R4, SO3R4, NR4R5, SO2NR4R5, SR4, CF3, CHF2, a 5- or a 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or a 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 hetero atoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by alkyl, halogen, O-alkyl, OH, NO2 or CF3, and where Ar may also be fused to a 5- or 6-membered carbocyclic, aromatic ring or to a 5- or 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 heteroatoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by -alkyl, halogen, O-alkyl, OH, NO2 or CF3; Het is a group of formulae (II); R1, R2 and R3 are, independently of one another, H, halogen, OR5, NR4R5, SR4, CF3, CN or alkyl which is unsubstituted or substituted by OH, O-alkyl or halogen; R4 is H or alkyl unsubstituted or substituted by OH, O-alkyl or halogen; R5 is the meaning indicated for R4 or is COR4 or CO2R4.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.021 seconds)
